Stifel Nicolaus analyst Stephen Willey upgraded the rating on Vor Biopharma to a Buy yesterday, setting a price target of $55.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Willey has given his Buy rating due to a combination of factors, including recent positive management discussions and the potential of telitacicept in treating a variety of autoimmune diseases. The stock’s nearly 40% decline over the past two months has improved its risk/reward profile, making it an attractive investment ahead of several upcoming catalysts by the end of 2025.
The recent acquisition of ex-China rights for telitacicept and the strategic restructuring of Vor Biopharma, including the addition of experienced leadership, further supports the Buy rating. The company’s ability to replicate telitacicept’s success in China on a global scale, particularly in competitive markets, is seen as a key driver for long-term value creation. The promising clinical data and the engineered advantages of telitacicept over competitors also contribute to the positive outlook for Vor Biopharma’s stock.
Willey covers the Healthcare sector, focusing on stocks such as Celcuity, Insmed, and Crescent Biopharma. According to TipRanks, Willey has an average return of 3.2% and a 40.33% success rate on recommended stocks.